Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
About this episode
This episode reviews recent advancements and datasets related to localized HR-positive breast cancer with insights from leading experts.
Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics: Introduction: ODAC — April 30, 2026 (00:00) Adjuvant CDK4/6 Inhibitors (13:03) Adjuvant Oral Selective Estrogen Receptor Degraders (21:53) Premenopausal Patients (30:52) Duration of Adjuvant Endocrine Treatment (38:44) Genomic Predictors of Chemotherapy Benefit (47:19) Neoadjuvant Treatment (55:13) CME information and select publications
People in this episode
Host: Dr. Neil Love
Guests: Dr Harold J Burstein, Dr Joyce O’Shaughnessy
Topics covered
- Localized HR-Positive Breast Cancer
- Adjuvant CDK4/6 Inhibitors
- Adjuvant Oral Selective Estrogen Receptor Degraders
- Premenopausal Patients
- Duration of Adjuvant Endocrine Treatment
- Genomic Predictors of Chemotherapy Benefit
- Neoadjuvant Treatment
Keywords
- breast cancer
- HR-positive
- CDK4/6 inhibitors
- selective estrogen receptor degraders
- adjuvant treatment
- genomic predictors
- neoadjuvant treatment
More episodes of Breast Cancer Update
- HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy
- For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress
- Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
- HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
- Metastatic Triple-Negative Breast Cancer — What Clinicians Want to Know
- HER2-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
Explore listener stats, chart rankings, contacts and more on the Breast Cancer Update podcast page.